R2 Technologies Inc. has received $10 million in funding from Huadong Medicine Company Limited as the third and final tranche of Huadong's $30 million Series B equity investment. R2's post-money valuation is $113 million, which is a predetermined valuation established at the time of the company's Series B close in June 2019. The funds will be used to launch R2 Technologies' first-to-market innovations: Glacial Rx is the first revolutionary CryoAesthetic age spot removal treatment, FDA-cleared to remove benign lesions and temporarily reduce pain, swelling and inflammation; and Glacial Spa is a cooling experience that brightens and evens skin tone.
Read more at PR Newswire >>